Lyra Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 145
- Market Cap
- $21.6M
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2
Lyra Therapeutics' pivotal Phase 3 ENLIGHTEN 2 trial of LYR-210, a bioresorbable nasal implant for chronic rhinosinusitis (CRS), is fully enrolled. LYR-210 delivers six months of continuous mometasone furoate therapy. Topline results expected Q2 2025.
© Copyright 2025. All Rights Reserved by MedPath